Vanessa Morales-Tirado’s Post

🔬 Exciting Advances in Disease Diagnosis with Biomlife by Ruhvenile® (www.ruhvenile.com)! 🔬 I'm thrilled to share the latest breakthrough in disease diagnosis with Biomlife! 🌐💡 Biomlife is at the forefront of revolutionizing healthcare by leveraging cutting-edge technologies to enhance disease detection and diagnosis. 🚀 Whether it's early cancer detection, infectious diseases, or chronic conditions, Biomlife's innovative solutions are making a significant impact. Key Features: ✅ Precision Medicine: Tailoring treatments based on individual patient characteristics. ✅ Data: Generate your own Biobank with BiomLife and analyse the specimen whenever you like with 2 years. ✅ Early Detection: Identifying diseases at their earliest stages for better prognosis. Our commitment to advancing healthcare is unwavering, and Biomlife is poised to reshape the landscape of disease diagnosis. Join us in the mission to make a positive impact on global health. Curious to learn more? Visit our website www.ruhvenile.com, email to [email protected] or reach out for a conversation +91 8587033367. Let's revolutionize healthcare together! 💪🏥 #Biomlife #DiseaseDiagnosis #HealthcareInnovation #Biotechnology #PrecisionMedicine #microbiomeresearch #hospital

Every Share Matters: April is Parkinson’s Awareness Month. Share this post to help raise awareness for the 90,000 people who are diagnosed with Parkinson’s disease in the United States. Scientists are exploring ways to identify Parkinson’s biomarkers, which could lead to earlier diagnosis and more personalized treatments. As someone is diagnosed with the disease every 6 minutes, the Parkinson’s Foundation encourages everyone to #Take6ForPD —using those 6 minutes to amplify Parkinson’s awareness. This April, the fight for improved Parkinson’s education and a cure continues! Share this post to help raise awareness and learn how the Parkinson’s Foundation is doing everything it can to improve the lives of people with Parkinson’s at https://www.parkinson.org #ParkinsonsAwarenessMonth #ParkinsonsDisease #Parkinsons #UniteForParkinsons

Is your research missing a critical dimension? The tissue microenvironment holds the key to understanding cellular behavior and disease progression. By studying the interactions between cells and their surroundings, researchers can gain valuable insights into disease mechanisms and develop more targeted therapies. Dive into this insightful research for a deeper understanding: 👇 https://lnkd.in/dwGFZFtd ➖ #TissueMicroenvironment #LifeScience #PrecisionMedicine #ScienceMatters #TargetedTherapies #ResearchCommunity

May is #LupusAwarenessMonth! At Alumis, we're committed to improving the lives of people living with lupus by shedding light on this complex autoimmune disease and advancing clinical research. Recognizing the disparities in #lupus care, especially in under-resourced regions, we’re proud to be a member of the Lupus Research Alliance 's Lupus Accelerating Breakthroughs Consortium (Lupus ABC), to pioneer better endpoints and advance more impactful clinical trials. Learn more how you can get involved in supporting the lupus community: https://lnkd.in/esmUVvvw #LupusAwareness #LupusResearch

Be the first to sign up and receive the preview of our lung e-book, https://lnkd.in/gD6jR9Ec co-authored by our head of lung development Megan Webster, PhD and their team. Including unique insights into our fibroblast to myofibroblast (FMT) assay, disease modelling applications and more. #LungEbook #LungFMT #SmallAirwaymodel

For the conclusion of our #BioIVTvision series of #2024Predictions, Shannon Richey, VP and GM of Disease State, sheds light on transformative changes ahead. Disease state testing, historically invasive, is undergoing a revolution. Biofluid testing on blood is enabling early #diseasedetection and helping build understanding of the uniqueness of each person's disease. Overall, biofluid testing promises to have game-changing impact on providing timely answers to patients about their conditions. “In 2024, I expect to see the transition accelerate from invasive tests to non-invasive tests that are done on blood through biofluid testing. The goal of this is to catch disease earlier and get answers to patients quicker, and if done correctly, there is a huge opportunity to look for cancers at a very early stage, for example.” - Shannon Richey, VP and GM at BioIVT #Biospecimens #Biotech

Today, on Glioblastoma Awareness Day, we honor the courageous patients and families who face the challenges of this relentless disease. Their unwavering spirit and resilience are truly worth celebrating. While significant progress has been made in enhancing diagnostics, early detection, and treatment of glioblastoma, there remains much to be accomplished. In our mission to raise awareness, we must acknowledge the groundbreaking impact of AI and real-world data research on diagnostics, early detection, and treatment. The remarkable strides made in understanding glioblastoma through advanced technologies and data analysis pave the way for personalized therapies and improved patient outcomes. Let us unite in support of those affected by glioblastoma and advocate for continued research. Together, we can make a meaningful difference in the fight against this formidable disease. #GlioblastomaAwarenessDay #BrainCancer #AIinHealthcare #RWD #EarlyDetection #CancerCare

"Having this comprehensive panel that can handle small volumes with high sensitivity is a game-changer for studying disease. We no longer need to focus on one or two cytokines at a time. We can look at a whole bunch of them and then extrapolate the entire immunological and clinical process.” Discover how Dr. Cuong Nguyen maximized the data yield from each valuable mouse subject by using just 1 µL of sample to analyze key immune mediators with Olink® Target 48 Mouse Cytokine panel: https://bit.ly/40LIhAh

Lot-to-lot consistency is an important requirement when performing cytokine analysis, with longitudinal studies of immune factors providing insight into immune response, inflammatory response, and disease. The MILLIPLEX Human Cytokine/Chemokine/Growth Factor Panel A from MilliporeSigma demonstrates consistent assay performance, sensitivity, and reproducible measurement of cytokines in serum and plasma between kit lots. Learn more about our partners’ newest product offerings in the latest xMAP® Resource Round-Up newsletter, now available in your inbox. Not yet a subscriber? Sign up now for the latest multiplexing updates, news, and product information in our free multiplexing newsletter: https://hubs.li/Q02rk01p0 #newsletter #xMAP #sciencenews #healthscience

Today is Rare Disease Day, a day to raise awareness and support for the millions of people living with rare diseases. Rare diseases are often complex and challenging to diagnose, treat, and monitor. That’s why PBL Assay Science is here to support researchers working in this area, whether it is scientific consultation related to monitor disease progression with various protein biomarker tools or biomarker assay development for these unique and rare targets. With decades of experience and being a forefront of biomarker research, we are here to help. Let’s show our stripes and stand together for rare disease patients and their families. #ShowYourStripes #rarediseaseday #PBLAssayScience #biomarkers